Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether CEP-701 given in sequence with induction
chemotherapy increases the proportion of patients with relapsed acute myeloid leukemia (AML)
who achieve a second complete remission (CR).